<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90824">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049853</url>
  </required_header>
  <id_info>
    <org_study_id>TripleA01</org_study_id>
    <nct_id>NCT02049853</nct_id>
  </id_info>
  <brief_title>The Triple A Initiative Study (&quot;Aktionsbündnis Akute Atemnot&quot;)</brief_title>
  <official_title>A Prospective Randomized Study of Coordinated Diagnostic Pathways and Treatment Algorithms for Patients With Acute Dyspnea Including Point-of-care Testing of a Cardiac Biomarker by the Emergency Medical Service Team</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Michael Christ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City Hospital Fuerth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayrisches Rotes Kreuz Fuerth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johanniter Unfall Hilfe Nürnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DRK-Kreisverbandes Jena-Eisenberg-Stadtroda e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Nürnberg</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute dyspnea is a common chief complaint of patients presenting to the emergency
      department. Patients with acute dyspnea display a high mortality rate. In-hospital mortality
      is as high as 10% during hospitalization and up to 30% within 6 months of follow-up. The
      Triple A Initiative Study is designed to improve the coordination of care for patients with
      acute dyspnea alerting the Emergency Medical Service (EMS). We hypothesize that the
      coordination of care starting at the EMS level including point-of-care testing of the
      cardiac biomarker NTproBNP will support preclinical and clinical diagnostic clarification.
      Treatment deriving from earlier diagnostic clarification will reduce length of stay in the
      hospital, treatment costs and improve patient's outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this prospective, randomized study is to evaluate the effects of point-of-care
      testing of NT-proBNP in patients presenting with acute dyspnea to the Emergency Medical
      Service (EMS).Patients will be enrolled in the Emergency Medical Services of participating
      German hospitals (Klinikum Nürnberg, Klinikum Fürth, Universitätsklinikum Jena). To be
      enrolled in the study, each patient must meet all of the following inclusion criteria and
      none of the exclusion criteria.

      Patients with acute dyspnea randomized to the POCT group will get a NT-proBNP-POCT
      measurement in the EMS. The emergency physician of the EMS will decide to apply predefined
      treatment strategies according to the resulting working hypothesis. Patients with acute
      dyspnea randomized to the standard care group will NOT get NT-proBNP measurement at the
      scene. The emergency physician of the ED will construct the working hypothesis following
      current treatment recommendations. The major focus of the study is to initiate treatment of
      heart failure as early as possible.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Days alive and out of hospital within 30 days</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis evaluating both costs and effects of alternative therapies (NT-proBNP vs. control group) at day 30, 90 and 180 days</measure>
    <time_frame>60 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of chest ultrasound to detect patients with acute heart failure</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital length of stay during follow-up of 30 and 90 days</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptoms (dyspnea) 24h, 48h, 72h hours after admission</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for ICU admission during initial hospitalization</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide level and calculated glomerular filtration rate at discharge</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients functional status at 30, 90 and 180 days (Barthel Index)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 30, 90 and 180 days</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total treatment costs at 30, 90 and 180 days</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital at 90 and 180 days</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Dyspnea</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>default group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with the randomization result &quot;default group&quot; receive standard diagnostics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POCT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with the randomization result &quot;POCT group&quot; receive a NTproBNP measurement with point of care device &quot;Cobash232&quot; in the ambulance vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NTproBNP measurement with point of care device &quot;Cobash232&quot; in the POCT group</intervention_name>
    <arm_group_label>POCT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute dyspnea (NYHA II-IV)

          -  age &gt;= 18 years

          -  informed consent

        Exclusion Criteria:

          -  cardiopulmonary resuscitation &lt; 7 days

          -  cardiogenic shock, STEMI, respiratory failure, or other clinical conditions that
             require immediate intensive care admission or angioplasty

          -  systolic blood pressure lower than 100 mmHg at first contact/presentation

          -  ventricular tachycardia

          -  severe aortic stenosis

          -  advanced neoplasm (e.g. lung cancer, hematologic neoplasm, etc.)

          -  chronic kidney disease requiring hemodialysis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Christ, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nürnberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Christ, Prof.</last_name>
    <phone>+49 911 398 2369</phone>
    <email>michael.christ@klinikum-nuernberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nuremberg</city>
        <state>Bavaria</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Christ, Prof.</last_name>
      <phone>+49 911 398 2369</phone>
      <email>michael.christ@klinikum-nuernberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Felicitas Geier, M. Sc.</last_name>
      <phone>+49 911 398 5561</phone>
      <email>felicitas.geier@klinikum-nuernberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Christ, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Fürth, Emergency Department</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Dormann, Prof.</last_name>
      <phone>+49 911 7580992808</phone>
      <email>harald.dormann@klinikum-fuerth.de</email>
    </contact>
    <investigator>
      <last_name>Harald Dormann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bayrisches Rotes Kreuz</name>
      <address>
        <city>Fürth</city>
        <zip>90762</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Milde</last_name>
      <phone>+49 911 77981-39</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Department of Anesthesiology and Intensive Care Medicine</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Winning, Dr.</last_name>
      <phone>+49 3641 9323101</phone>
      <email>Johannes.Winning@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Winning, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK-Kreisverbandes Jena-Eisenberg-Stadtroda e.V.</name>
      <address>
        <city>Jena</city>
        <zip>07749</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johanniter-Unfall-Hilfe</name>
      <address>
        <city>Nuremberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Seitz</last_name>
      <phone>+49 911 27257 50</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Nürnberg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Michael Christ</investigator_full_name>
    <investigator_title>Prof. Dr. med. Michael Christ</investigator_title>
  </responsible_party>
  <keyword>acute dyspnea</keyword>
  <keyword>heart failure</keyword>
  <keyword>diagnostics</keyword>
  <keyword>POCT analysis</keyword>
  <keyword>preclinical area</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
